CClinicalTrials.gg
RecruitingNCT06161311Updated Oct 2, 2024

Baseline Relative Peripheral Refraction in Myopia Control

A Phase 2 interventional study of DIMS lenses in Myopia, sponsored by The Hong Kong Polytechnic University. Recruiting at 1 site in Hong Kong. Open to participants aged 6 Years to 9 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by The Hong Kong Polytechnic University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
6 Years to 9 Years
Sex
All
01

Study summary

Myopia has become a world concern and its prevalence has increased in recent decades. Myopic defocus has been applied for slowing down the axial elongation and myopia progression, which is mainly based on the theory of simultaneous competing defocus and peripheral optics. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses impose myopic defocus in the central or peripheral retina, with myopia progression being retarded by 50% to 60%. However, the optimal amount of myopic defocus has not yet been determined. Relative peripheral refraction (RPR) is used to indicate the difference between peripheral refraction and central refraction. Previous studies showed that retinal shape determined RPR, and baseline RPR may influence the myopia control efficacy using DIMS lenses on myopic children. It is still unclear if any other unknown factor influenced the final myopia control outcome in these young children with myopic RPR at baseline. Unlike our previous study8 that bias on hyperopic RPR children (myopic RPR, n = 27; hyperopic RPR, n = 52), this study is a case-control study with the same sample size for each RPR group. We will also include younger children who are more prone to have myopic RPR and develop high myopia. The results should provide new insight into the myopia control strategy in early-onset myopic children.

In the current study, we will investigate the influence of baseline RPR in myopia retardation using DIMS lenses among young myopic children.

This will ba a 1-year prospective clinical trial. Through G*Power (version 3.1.9.6) calculation, 80 healthy myopic subjects (40 myopic RPR vs 40 hyperopic RPR) aged 5-9 years should be needed. After screened by inclusion criteria, eligible participants will be assigned to wear DIMS lenses for 1 year (12 months, 8 hour per day, 7 days per week). This study includes 5 visits: Visit 1: baseline, Visit 2: lens dispensing, Visit 3: 2-week follow-up, Visit 4: 6-month follow-up, and Visit 5: 12-month follow-up. All eye examinations will be carried out in the Optometry Research Centre (A137), the School of Optometry, the Hong Kong Polytechnic University. The main data collection, including refractive error, axial length, related ocular parameters will be measured at baseline, 6-month and 1-year visits. At the lens dispensing and 2-week follow-up visits, vision acuity testing and computer scanning of posterior eyes will be measured. New DIMS lens will be replaced and upgraded if the equivalent sphere of refraction (SER) is changed or visual acuity change.

The following data will be statistically analyzed. The primary outcome data include the difference in change in SER with cycloplegia between the myopic and hyperopic RPR from the baseline over 12 months of treatment. Secondary outcomes data include the changes in axial length, peripheral refraction, relative peripheral refraction, the amplitude of accommodation, lag of accommodation, corneal curvature, phoria and stereoacuity.

02

Conditions studied

  • Myopia

Browse trials for

03

In context

Myopia

984 studies on the registry are indexed under Myopia; 210 are open to participants now.

This study's planned enrollment of 80 is close to the median of 80 across 783 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 659 studies on the registry; 250 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age at enrolment: 6-9 years
  • Spherical equivalent refraction (SER): -0.75 to -5.00 Diopters (D)
  • Astigmatism: -1.50 D or less
  • Anisometropia: 1.50 D or less
  • Spectacle best-corrected monocular visual acuity (VA): 0.00 logMAR or better

Exclusion criteria

Exclusion Criteria:

  • Ocular and systemic abnormalities might affect visual functions or refractive development
  • Prior use of any drugs or optical devices of myopia control treatment.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Myopic RPR group

    Patients with myopic relative peripheral refraction

    Device: DIMS lenses

  • Active comparator
    Hyperopic RPR group

    Patients with hyperopic relative peripheral refraction

    Device: DIMS lenses

Interventions

  • DeviceDIMS lenses

    Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children

06

What researchers measure

Primary outcomes

  1. Cycloplegic refractive error

    Refractive error measured after instillation of cycloplegia

    Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment

Secondary outcomes

  1. Axial length

    Length of the eye

    Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment

  2. Peripheral refraction

    Refractive errors at peripheral fields

    Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment

  3. Amplitude and lag of accommodation

    Ability of the eyes to accommodate

    Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment

  4. Corneal curvature

    Power of the cornea

    Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment

  5. Phoria and stereoacuity

    Coordination of the two eyes

    Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06161311
Lead sponsor
The Hong Kong Polytechnic University
Collaborators
Centre for Eye and Vision Research, HOYA Lamphun Ltd
Responsible party
LEUNG Tsz Wing (Research Assistant Professor, The Hong Kong Polytechnic University) — Principal investigator
First posted
Dec 7, 2023
Start date
Dec 1, 2023
Primary completion
Apr 3, 2025 (estimated)
Completion
Apr 3, 2025 (estimated)
Last update
Oct 2, 2024

Study contacts

Tsz Wing Leung, PhD
Contact
jeffrey.TW.leung@polyu.edu.hk
27664268

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion